References
- National Osteoporosis Foundation, Washington, DC [online]. Available from http://www.nof.org/osteoporosis/index.htm. [Accessed August 2003]
- Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. J Am Med Assoc 1999;282:1344–52
- Reginster J, Minnie HW, Sörensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 2002;11:83–9
- McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. New Engl J Med 2001;344:333–40
- Brown JP, Kendler DL, McClung MR, et al. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int 2002;71: 103–11
- Watts NB, Lindsay R, Li Z, Kasibhatla C, Brown J. Use of matched historical controls to evaluate the anti-fracture efficacy of once-a-week risedronate. Osteoporos Int 2003;14:437–41
- Genant HK, Wu CY, van Kuijk C, Nevitt MC. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 1993;8:1137–48
- Watts NB, Lindsay R, Li Z, Brown J. Vertebral fracture risk reduction over two years with risedronate 35 mg once a week. Osteoporos Int 2002;3:S40
- Gehan EA. The evaluation of therapies: historical control studies. Stat Med 1984;3:315–24